Chemoprevention of Active Scutellaria baicalensis Fraction on Colon Cancer

黄芩活性部位对结肠癌的化学预防作用

基本信息

  • 批准号:
    8638895
  • 负责人:
  • 金额:
    $ 9.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Colorectal cancer is a leading cause of cancer-related death in the United States. Numerous effective anticancer drugs have been developed from botanicals, and identifying new herbal sources to develop ideal chemoprevention remains an essential step in advancing the treatment of colorectal cancer. The candidate, Dr. Chong-Zhi Wang, is an experienced phytochemical scientist at University of Chicago. This application describes a development award for Dr. Wang, to successfully achieve his long-term career goals of obtaining the skills necessary to become an independent investigator in biomedical research, concentrating on the efficacy and mechanism of bioactive botanical extracts/compounds for treating colorectal cancer. Training for Dr. Wang will focus on advancing his knowledge of pharmacognosy and metabolism of phytoconstituents, understanding cancer pathophysiology, becoming proficient in biostatistics knowledge, and improving his grant writing ability. The advisory team is composed of senior experts from the University of Chicago and University of Illinois at Chicago. The Primary Mentor Dr. Chun-Su Yuan, a Principal Investigator of NIH Center for Botanical Research on Colorectal Cancer at University of Chicago, will closely direct Dr. Wang's training and research. Preliminary data showed that the different fractions from Scutellaria baicalensis extract (SbE) had opposing effects on human colorectal cancer cells. The hypothesis of this study is that if the baicalin and scutellarein, hydrophilic constituents, are removed from S. baicalensis extract or transformed into lipophilic constituents, the anticancer effects of the extract will increase significantly. The purpose of the research is to develop a new process for preparing an aglycon-rich fraction (ARF) of S. baicalensis extract in improving its anticancer activities and to elucidate the underlying mechanisms. The specific aims are as follows: Aim 1. Authentication, extraction and isolation of SbE and preparation of ARF. Aim 2. Evaluation of the effects of SbE and ARF on colorectal cancer and related mechanisms of action. Aim 3. Further investigation of ARF-induced apoptotic pathways. Data from this proposed study will have the potential to advance cancer treatment regimens, and improve the quality of life for patients suffering from colorectal cancer. Upon successful completion of this award, Dr. Wang will be fully prepared for his independent investigation of additional pharmacologically based studies using phytoconstituents against colorectal cancer.
描述(由申请人提供):结直肠癌是美国癌症相关死亡的主要原因。许多有效的抗癌药物已经从植物中开发出来,寻找新的草药来源来开发理想的化学预防仍然是推进结直肠癌治疗的重要一步。候选人王崇志博士是芝加哥大学经验丰富的植物化学科学家。该申请描述了王博士的发展奖励,以成功实现他的长期职业目标,即获得成为生物医学研究独立研究者所需的技能,专注于生物活性植物提取物/化合物治疗结直肠癌的功效和机制。对王博士的培训将侧重于提高他的生药学和植物成分代谢知识,了解癌症病理生理,熟练掌握生物统计学知识,提高他的论文写作能力。咨询小组由来自芝加哥大学和伊利诺伊大学芝加哥分校的资深专家组成。主要导师袁春素博士是美国国立卫生研究院芝加哥大学结直肠癌植物研究中心的首席研究员,他将密切指导王博士的培训和研究。初步研究表明,黄芩提取物的不同部位对人大肠癌细胞的杀伤作用相反。本研究的假设是,将黄芩提取物中的亲水成分黄芩苷和黄芩苷去除或转化为亲脂性成分,可以显著提高黄芩提取物的抗癌作用。本研究的目的是开发一种制备黄芩提取物富糖共聚物(ARF)的新工艺,以提高黄芩提取物的抗癌活性,并阐明其作用机制。具体目标如下:目标1。SbE的鉴定、提取分离及ARF的制备。目标2。SbE和ARF对结直肠癌的作用及其作用机制的评价。目标3。arf诱导的凋亡通路的进一步研究。这项拟议研究的数据将有可能推进癌症治疗方案,并改善结直肠癌患者的生活质量。在成功完成该奖项后,王博士将充分准备他的独立研究,利用植物成分对抗结直肠癌的其他药理学研究。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis of surface nano-molecularly imprinted polymers for sensitive baicalin detection from biological samples.
表面纳米分子印迹聚合物的合成,用于生物样品中黄芩苷的灵敏检测
  • DOI:
    10.1039/c5ra04424c
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Gu X;He H;Wang CZ;Gao Y;Zhang H;Hong J;Du S;Chen L;Yuan CS
  • 通讯作者:
    Yuan CS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chong-Zhi Wang其他文献

Chong-Zhi Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chong-Zhi Wang', 18)}}的其他基金

Chemoprevention of Active Scutellaria baicalensis Fraction on Colon Cancer
黄芩活性部位对结肠癌的化学预防作用
  • 批准号:
    8448686
  • 财政年份:
    2010
  • 资助金额:
    $ 9.82万
  • 项目类别:
Chemoprevention of Active Scutellaria baicalensis Fraction on Colon Cancer
黄芩活性部位对结肠癌的化学预防作用
  • 批准号:
    8233477
  • 财政年份:
    2010
  • 资助金额:
    $ 9.82万
  • 项目类别:
Chemoprevention of Active Scutellaria baicalensis Fraction on Colon Cancer
黄芩活性部位对结肠癌的化学预防作用
  • 批准号:
    8050095
  • 财政年份:
    2010
  • 资助金额:
    $ 9.82万
  • 项目类别:
Chemoprevention of Active Scutellaria baicalensis Fraction on Colon Cancer
黄芩活性部位对结肠癌的化学预防作用
  • 批准号:
    7894018
  • 财政年份:
    2010
  • 资助金额:
    $ 9.82万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了